|Systematic (IUPAC) name|
|CAS Registry Number|
|Molecular mass||500.277 g/mol|
|(what is this?)|
Satraplatin (INN, codenamed JM216) is a platinum-based antineoplastic agent that is under investigation as one treatment of patients with advanced prostate cancer who have failed previous chemotherapy. It has not yet received approval from the U.S. Food and Drug Administration. First mentioned in the medical literature in 1993, satraplatin is the first orally active platinum-based chemotherapeutic drug; other available platinum analogues—cisplatin, carboplatin, and oxaliplatin—must be given intravenously.
It is made available in the United States jointly by Spectrum Pharmaceuticals and GPC Biotech under the name SPERA (SatraPlatin Expanded Rapid Access).
- Wheate, Nial J.; Walker, Shonagh; Craig, Gemma E.; Oun, Rabbab (2010). "The status of platinum anticancer drugs in the clinic and in clinical trials". Dalton Transactions 39 (35): 8113–27. doi:10.1039/C0DT00292E. PMID 20593091.
- Kelland LR, Abel G, McKeage MJ, et al. (1993). "Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug" (PDF). Cancer Res 53 (11): 2581–6. PMID 8388318.
- Choy H, Park C, Yao M (2008). "Current status and future prospects for satraplatin, an oral platinum analogue". Clin Cancer Res 14 (6): 1633–8. doi:10.1158/1078-0432.CCR-07-2176. PMID 18347164.
- Satraplatin — Spectrum Pharmaceuticals
|This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.|